In this episode of Raising Biotech, host Surani Fernando speaks with Mike Curtis, CEO of eGenesis, and Dr. Adam Griesemer, Associate Professor of Surgery at NYU Langone Health. The episode covers eGenesis’s origins, its fundraising journey, and its pioneering work in xenotransplantation—using genetically modified pigs to develop viable organs for human transplants.
eGenesis was founded in 2015, building on the research of Harvard scientists George Church and Luhan Yang, who demonstrated the potential of CRISPR technology to inactivate harmful pig viruses (PERVs). This breakthrough set the foundation for eGenesis’s mission to create genetically modified pigs as a reliable source of human-compatible organs. Backed by prominent healthcare investors, the company has secured over $250 million in funding, underscoring the potential impact of its technology on the global organ shortage crisis.
The episode delves into the science behind eGenesis’s platform. Curtis explains how their technology involves making numerous genetic edits to reduce immune rejection and eliminate risks associated with viral transmission. Their genetically modified pig kidneys have already shown promising results in preclinical studies, surviving for over two years in monkey models. Dr. Griesemer provides an expert perspective, noting the significance of these advancements while also highlighting ongoing debates about the optimal number of genetic edits required for successful outcomes.
As eGenesis moves toward clinical trials, Curtis discusses the company’s collaborative work with regulatory bodies like the FDA and their plans to conduct trials in both the U.S. and Japan. The initial trials will likely target older patients who have limited options, aiming to demonstrate the safety and effectiveness of their technology in a controlled, low-risk setting.
The road ahead is not without challenges. Scaling the genetically modified pigs for widespread use poses logistical and scientific hurdles, including breeding efficiency and the potential reliance on cloning. Dr. Griesemer highlights these complexities, suggesting that scaling up production to meet patient needs will require significant time and resources.
From a business perspective, eGenesis remains proactive in seeking partnerships and additional funding to support its growth and upcoming trials. Curtis indicates that an IPO is on the horizon as the company scales its platform and looks toward accessing public markets for capital needed to expand manufacturing and distribution capabilities.
eGenesis’s journey is just beginning as they navigate the complexities of xenotransplantation, genetic engineering, and regulatory pathways.
Curious about how eGenesis is tackling the organ shortage crisis through cutting-edge science and strategic business moves? Tune into the full episode of Raising Biotech to hear more insights from CEO Mike Curtis and Dr. Adam Griesemer.
[This episode was published on 28 November 2023]